Your Patients Need Your Help Navigating Elevidys Access

For families managing Duchenne muscular dystrophy (DMD), the prospect of gene therapy with Elevidys (Delandistrogene Moxeparvovec-rokl) represents profound hope. But the reality of accessing a $3.2 million one-time treatment with a Boxed Warning, limited treatment centers, and complex insurance requirements can be overwhelming.

As their provider, you're uniquely positioned to help. This guide covers the current availability landscape, why patients struggle to access Elevidys, and concrete steps you can take to improve their chances.

Current Availability Status

As of early 2026, Elevidys is available for ambulatory DMD patients aged 4 and older with a confirmed amenable DMD gene mutation. Key supply factors:

• Shipments resumed for ambulatory patients following the July 2025 voluntary pause
• Non-ambulatory indication withdrawn — these patients are no longer eligible
• Weight-based kits (including the 21.5-22.4 kg kit) must be ordered specifically for each patient
• Treatment centers are limited to specialized neuromuscular disease facilities with gene therapy capabilities
• Manufacturing capacity may affect kit availability for certain weight bands

Why Patients Can't Find Elevidys

Understanding the specific barriers helps you address them proactively:

Insurance Authorization Complexity

The $3.2 million price point triggers the most rigorous level of payer review. Common barriers include:

• Multi-step prior authorization with clinical documentation requirements
• Mandatory peer-to-peer reviews with payer medical directors
• Initial denials that require formal appeals (often multiple rounds)
• Medical benefit vs. pharmacy benefit classification confusion
• Single-case agreements for gene therapies not yet in standard coverage policies

Limited Treatment Center Network

Gene therapy infusion requires infrastructure that most hospitals don't have:

• Specialized neuromuscular care teams experienced with AAV-based therapies
• Capacity for extended post-infusion monitoring including hepatic surveillance
• Emergency protocols for managing acute liver injury and other serious adverse events
• Pharmacy capability for handling weight-based kit preparation

Post-2025 Safety Concerns

The Boxed Warning for fatal liver injury has understandably created hesitation among some families and institutions. Some treatment centers are proceeding more cautiously with patient selection and have adjusted their eligibility criteria beyond the minimum FDA requirements.

What Providers Can Do: 5 Steps

Step 1: Verify Eligibility Thoroughly

Before initiating the access process, confirm your patient meets all current criteria:

• Ambulatory status (document with standardized assessments such as the North Star Ambulatory Assessment)
• Age 4 years or older
• Confirmed DMD gene mutation with genetic test results amenable to treatment
• No deletion affecting DMD gene exons 8 or 9
• No preexisting liver impairment (baseline LFTs within normal limits)
• No recent live vaccinations (assess vaccination timeline)
• No recent or active infections

Thorough eligibility documentation upfront prevents costly delays later in the authorization process.

Step 2: Build a Comprehensive Prior Authorization Package

A strong initial submission reduces the likelihood of denial:

• Genetic test results clearly showing the DMD mutation
• Clinical notes documenting ambulatory status with objective assessments
• Letter of medical necessity citing the clinical rationale, disease trajectory, and time-sensitivity of treatment
• Published evidence supporting Elevidys efficacy in ambulatory patients
• Contra-indication for alternatives if applicable (e.g., patient's mutation is not amenable to exon-skipping therapies)

SareptAssist offers templates and authorization support — call 1-888-727-3782.

Step 3: Coordinate With an Active Treatment Center

Contact treatment centers that are currently administering Elevidys to:

• Confirm they are accepting new patients
• Understand their specific intake requirements
• Coordinate the referral process
• Align on timing with insurance authorization

If your institution doesn't administer Elevidys, establishing a referral relationship with a center that does is critical. SareptAssist can provide current treatment center information.

Step 4: Prepare the Family for the Process

Set realistic expectations about timelines and requirements:

• The entire process from initial assessment to infusion can take several months
• Insurance denials and appeals are common — this doesn't mean treatment won't happen
• Pre-treatment corticosteroid protocol begins the day before infusion
• Post-infusion monitoring requires a minimum 60-day corticosteroid course and serial lab work
• Travel may be necessary if no local treatment center is available

Step 5: Leverage Support Resources

Don't try to manage the entire access process alone:

• SareptAssist: Dedicated provider and patient support — 1-888-727-3782
• Medfinder for Providers: Track medication availability and access resources
• PPMD (Parent Project Muscular Dystrophy): Care navigation and family support
• MDA (Muscular Dystrophy Association): Care center network and treatment access

Alternative Treatments to Optimize While Waiting

While pursuing Elevidys access, ensure your patient's current treatment regimen is optimized:

• Deflazacort (Emflaza): First-line corticosteroid; confirm appropriate dosing
• Exon-skipping therapies: If the patient's mutation is amenable (exon 45: Casimersen/Amondys 45; exon 51: Eteplirsen/Exondys 51; exon 53: Viltolarsen/Viltepso)
• Cardiac monitoring: Regular echocardiography and consideration of cardioprotective therapy
• Physical therapy: Continued focus on maintaining function and preventing contractures

For more on alternatives, see our Elevidys alternatives article.

Workflow Tips for Your Practice

• Designate a gene therapy coordinator within your practice to manage the Elevidys process for all DMD patients
• Create a tracking system for each patient's authorization status, treatment center communication, and key milestones
• Schedule regular check-ins with families (monthly minimum) to update them on progress and address concerns
• Document everything — detailed clinical notes support both initial authorization and appeal submissions
• Build relationships with treatment center coordinators and SareptAssist representatives for smoother collaboration

Final Thoughts

Helping a patient access Elevidys requires significant time and effort, but for eligible ambulatory DMD patients, this one-time gene therapy represents a meaningful treatment option. Your role in verifying eligibility, building strong authorization packages, coordinating with treatment centers, and supporting families through the process is irreplaceable.

For additional provider resources, explore our articles on the current Elevidys shortage from a provider perspective, helping patients manage costs, and drug interactions to consider.